Skip to main content
Fig. 4 | Experimental Hematology & Oncology

Fig. 4

From: Refractory myeloid sarcoma with a FIP1L1-PDGFRA rearrangement detected by clinical high throughput somatic sequencing

Fig. 4

Radiology evaluation of disease burden after imatinib treatment. a PET-CT 4 weeks after initiation of imatinib treatment showing marked interval improvement in supradiaphragmatic and infradiaphragmatic lymphadenopathy as well as the skeletal/marrow disease burden. b PET-CT 6 months post imatinib treatment and 4 months reduced-intensity conditioning allogeneic stem cell transplantation shows no FDG-avid malignancy

Back to article page

Experimental Hematology & Oncology

ISSN: 2162-3619

Contact us